Literature DB >> 313960

Characterization of a spontaneous murine B cell leukemia (BCL1). I. Cell surface expression of IgM, IgD, Ia, and FcR.

M R Knapp, P P Jones, S J Black, E S Vitetta, S Slavin, S Strober.   

Abstract

The surface marker expression of a spontaneous B lymphocyte leukemia discovered in a BALB/c mouse (BCL1) was examined and found to include a subset of markers known to occur on normal B lymphocytes. The tumor cells bore surface Ig that included both mu- and delta-chains associated with the lambda light chain. Alloantigens coded for within the murine MHC, including H-2D, H-2K, and I-region products, were identified on the tumor cells. Although normal B lymphocytes are thought to express products coded for within both the I-A and I-E subregions, the BCL1 expressed only normal amounts of I-E subregion products. In addition, the H-2 and Ia antigens revealed by 2-dimensional gel electrophoresis exhibited an abnormal pattern of post-translational modifications. The Fc, but not the complement-receptor, was present on the surface of tumor cells. The presence of IgD, Ia antigens, and the responsiveness to lipopolysaccharide (see subsequent paper) have led us to postulate that the BCL1 tumor represents a later differentiative stage than murine B lymphocyte tumors previously described.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 313960

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  Coexpression of mu and gamma 1 heavy chains can occur by a discontinuous transcription mechanism from the same unrearranged chromosome.

Authors:  M Nolan-Willard; M T Berton; P Tucker
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-15       Impact factor: 11.205

2.  Frequent lambda light chain gene rearrangement and expression in a Ly-1 B lymphoma with a productive kappa chain allele.

Authors:  R R Hardy; J L Dangl; K Hayakawa; G Jager; L A Herzenberg; L A Herzenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

Review 3.  Path to clinical transplantation tolerance and prevention of graft-versus-host disease.

Authors:  Samuel Strober
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

4.  Signaling to a B-cell clone by Ek, but not Ak, does not reflect alteration of Ak genes.

Authors:  G A Bishop; M S McMillan; G Haughton; J A Frelinger
Journal:  Immunogenetics       Date:  1988       Impact factor: 2.846

5.  BCL1, a murine model of prolymphocytic leukemia. II. Morphology and ultrastructure.

Authors:  M J Muirhead; J M Holbert; J W Uhr; E S Vitetta
Journal:  Am J Pathol       Date:  1981-12       Impact factor: 4.307

6.  Simultaneous expression of immunoglobulin mu and delta heavy chains by a cloned B-cell lymphoma: a single copy of the VH gene is shared by two adjacent CH genes.

Authors:  M R Knapp; C P Liu; N Newell; R B Ward; P W Tucker; S Strober; F Blattner
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

7.  Induction of proliferation and differentiation of neoplastic B cells by anti-immunoglobulin and T-cell factors.

Authors:  P C Isakson; E Puré; J W Uhr; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  1981-04       Impact factor: 11.205

8.  BCL1, a murine model of prolymphocytic leukemia. I. Effect of splenectomy on growth kinetics and organ distribution.

Authors:  M J Muirhead; P C Isakson; K A Krolick; J W Uhr; E S Vitetta
Journal:  Am J Pathol       Date:  1981-12       Impact factor: 4.307

9.  Increased expression of myc-related oncogene mRNA characterizes most BALB/c plasmacytomas induced by pristane or Abelson murine leukemia virus.

Authors:  J F Mushinski; S R Bauer; M Potter; E P Reddy
Journal:  Proc Natl Acad Sci U S A       Date:  1983-02       Impact factor: 11.205

10.  Induction of tumor immunity by intact irradiated leukemic B cells (BCL1) bearing a tumor-associated cell-surface idiotype and the costimulatory B7 molecule.

Authors:  S Morecki; S Levi; Y Puyesky; S Slavin
Journal:  Cancer Immunol Immunother       Date:  1995-10       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.